MeHow Innovative Ltd. A vs Imeik Technology Development: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

MeHow Innovative Ltd. A (301363.CS)

Q3 202627 Jul – 22 Sep 2026

▲3

BCI patent and client tie-ups drive MeHow; H1 profit up 8.8%

BCI patent strengthens technology position MeHow published a patent for a self-generating neural electrode that tackles long-term implant problems like rising impedance and weakening signals. This keeps it central to invasive brain-computer interface hardware, a fast-growing niche, and supports future demand for its electrode components.
A company-specific technology milestone that directly boosts its competitive position in the BCI supply chain.
Technical cooperation with domestic BCI clients MeHow said it is working closely with domestic brain-computer interface customers, helping them move from lab testing to large-scale commercial production. This positions the company to benefit as the BCI industry shifts from research to real sales, adding a new growth driver beyond its core medical device business.
Shows concrete commercial progress with BCI clients, a key new demand source for the company.
First-half profit rises 8.8% on higher revenue MeHow reported H1 net profit of 124 million yuan, up 8.8%, and revenue of 813 million yuan, up 11.0%. Operating cash flow jumped 48.3%, showing the core business is healthy and generating more cash, which supports the stock's fundamental value.
The interim results confirm steady earnings growth and strong cash generation, a core support for the share price.
Restricted share incentive plan at 8.49 yuan MeHow plans to grant 6.07 million restricted shares to up to 496 core employees at 8.49 yuan each. This ties staff to the company's long-term success, a positive for retention, but the low grant price can dilute existing shareholders and may cap near-term upside.
A new equity event that affects ownership and employee alignment, with both supportive and dilutive effects.

August 202627 Jul – 22 Sep 2026

▲3

BCI patent and client tie-ups drive MeHow; H1 profit up 8.8%

BCI patent strengthens technology position MeHow published a patent for a self-generating neural electrode that tackles long-term implant problems like rising impedance and weakening signals. This keeps it central to invasive brain-computer interface hardware, a fast-growing niche, and supports future demand for its electrode components.
A company-specific technology milestone that directly boosts its competitive position in the BCI supply chain.
Technical cooperation with domestic BCI clients MeHow said it is working closely with domestic brain-computer interface customers, helping them move from lab testing to large-scale commercial production. This positions the company to benefit as the BCI industry shifts from research to real sales, adding a new growth driver beyond its core medical device business.
Shows concrete commercial progress with BCI clients, a key new demand source for the company.
First-half profit rises 8.8% on higher revenue MeHow reported H1 net profit of 124 million yuan, up 8.8%, and revenue of 813 million yuan, up 11.0%. Operating cash flow jumped 48.3%, showing the core business is healthy and generating more cash, which supports the stock's fundamental value.
The interim results confirm steady earnings growth and strong cash generation, a core support for the share price.
Restricted share incentive plan at 8.49 yuan MeHow plans to grant 6.07 million restricted shares to up to 496 core employees at 8.49 yuan each. This ties staff to the company's long-term success, a positive for retention, but the low grant price can dilute existing shareholders and may cap near-term upside.
A new equity event that affects ownership and employee alignment, with both supportive and dilutive effects.

Latest27 Jul – 22 Sep 2026

▲3

BCI patent and client tie-ups drive MeHow; H1 profit up 8.8%

BCI patent strengthens technology position MeHow published a patent for a self-generating neural electrode that tackles long-term implant problems like rising impedance and weakening signals. This keeps it central to invasive brain-computer interface hardware, a fast-growing niche, and supports future demand for its electrode components.
A company-specific technology milestone that directly boosts its competitive position in the BCI supply chain.
Technical cooperation with domestic BCI clients MeHow said it is working closely with domestic brain-computer interface customers, helping them move from lab testing to large-scale commercial production. This positions the company to benefit as the BCI industry shifts from research to real sales, adding a new growth driver beyond its core medical device business.
Shows concrete commercial progress with BCI clients, a key new demand source for the company.
First-half profit rises 8.8% on higher revenue MeHow reported H1 net profit of 124 million yuan, up 8.8%, and revenue of 813 million yuan, up 11.0%. Operating cash flow jumped 48.3%, showing the core business is healthy and generating more cash, which supports the stock's fundamental value.
The interim results confirm steady earnings growth and strong cash generation, a core support for the share price.
Restricted share incentive plan at 8.49 yuan MeHow plans to grant 6.07 million restricted shares to up to 496 core employees at 8.49 yuan each. This ties staff to the company's long-term success, a positive for retention, but the low grant price can dilute existing shareholders and may cap near-term upside.
A new equity event that affects ownership and employee alignment, with both supportive and dilutive effects.

Imeik Technology Development Co (300896.CS)

Q3 202615 Jul – 28 Sep 2026

▼3▲1

Imeik profit slumps as costs surge; new product approvals offer offset

First-half profit and sales both fell sharply Imeik's first-half revenue fell 6.42% to 1.216 billion yuan and net profit dropped 24.84% to 593 million yuan. Selling expenses jumped 63%, squeezing margins. Core injectable products shrank, so the market sees weaker earnings power and marks the stock down.
The half-year earnings miss is the main force weighing on the stock this period.
Goodwill risk from the REGEN acquisition Goodwill of 1.641 billion yuan sits on the balance sheet, 1.305 billion of it from buying South Korea's REGEN. If that business underperforms, the company must write it down, which would hit reported profit again. This adds uncertainty on top of the earnings decline.
It is a concrete balance-sheet risk that can hurt future profit and investor confidence.
New product approvals broaden the product line Imeik won approval for a sodium hyaluronate gel medical device and, in September, a lidocaine-tetracaine numbing cream used in filler and laser procedures. These add sellable products and support future revenue, though they take time to contribute meaningfully.
Approvals are the clearest positive counterweight to the weak earnings.
Botulinum toxin still not launched Imeik said its botulinum toxin product is not yet on sale, with the sales team only doing pre-launch work. This delays a much-anticipated new growth driver, so expected future revenue from it keeps getting pushed out.
A delayed key product launch removes a hoped-for growth catalyst.

August 202615 Jul – 28 Sep 2026

▼3▲1

Imeik profit slumps as costs surge; new product approvals offer offset

First-half profit and sales both fell sharply Imeik's first-half revenue fell 6.42% to 1.216 billion yuan and net profit dropped 24.84% to 593 million yuan. Selling expenses jumped 63%, squeezing margins. Core injectable products shrank, so the market sees weaker earnings power and marks the stock down.
The half-year earnings miss is the main force weighing on the stock this period.
Goodwill risk from the REGEN acquisition Goodwill of 1.641 billion yuan sits on the balance sheet, 1.305 billion of it from buying South Korea's REGEN. If that business underperforms, the company must write it down, which would hit reported profit again. This adds uncertainty on top of the earnings decline.
It is a concrete balance-sheet risk that can hurt future profit and investor confidence.
New product approvals broaden the product line Imeik won approval for a sodium hyaluronate gel medical device and, in September, a lidocaine-tetracaine numbing cream used in filler and laser procedures. These add sellable products and support future revenue, though they take time to contribute meaningfully.
Approvals are the clearest positive counterweight to the weak earnings.
Botulinum toxin still not launched Imeik said its botulinum toxin product is not yet on sale, with the sales team only doing pre-launch work. This delays a much-anticipated new growth driver, so expected future revenue from it keeps getting pushed out.
A delayed key product launch removes a hoped-for growth catalyst.

Latest15 Jul – 28 Sep 2026

▼3▲1

Imeik profit slumps as costs surge; new product approvals offer offset

First-half profit and sales both fell sharply Imeik's first-half revenue fell 6.42% to 1.216 billion yuan and net profit dropped 24.84% to 593 million yuan. Selling expenses jumped 63%, squeezing margins. Core injectable products shrank, so the market sees weaker earnings power and marks the stock down.
The half-year earnings miss is the main force weighing on the stock this period.
Goodwill risk from the REGEN acquisition Goodwill of 1.641 billion yuan sits on the balance sheet, 1.305 billion of it from buying South Korea's REGEN. If that business underperforms, the company must write it down, which would hit reported profit again. This adds uncertainty on top of the earnings decline.
It is a concrete balance-sheet risk that can hurt future profit and investor confidence.
New product approvals broaden the product line Imeik won approval for a sodium hyaluronate gel medical device and, in September, a lidocaine-tetracaine numbing cream used in filler and laser procedures. These add sellable products and support future revenue, though they take time to contribute meaningfully.
Approvals are the clearest positive counterweight to the weak earnings.
Botulinum toxin still not launched Imeik said its botulinum toxin product is not yet on sale, with the sales team only doing pre-launch work. This delays a much-anticipated new growth driver, so expected future revenue from it keeps getting pushed out.
A delayed key product launch removes a hoped-for growth catalyst.